Ormond disease is a dubious disease in the field of autoimmunity and rheumatic immunity, clinical performance is complex and often involves multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of Ormond disease requires individualized development of treatment programs, usually including drug therapy, rehabilitation interventions, and regular follow-up multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved.
Treatment requires close monitoring of therapeutic efficacy and adverse reactions and timely adaptation to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of Ormond disease. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of autoimmune and rheumatic immunity, to provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.